Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality
PLOS Global Public Health · 01.09.2023 · 3 (9) · e0001989
DOI: 10.1371/journal.pgph.0001989 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Global Public Health, online erschienen am 01.09.2023. Verfasst von Elise De Vos und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Antwerp, Antwerp, Belgium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek, Office of AIDS Research.
Abstract (Originalsprache)
Studies assessing patient-centred outcomes of novel rifampicin resistant tuberculosis (RR-TB) diagnostics are rare and mostly apply conventional methods which may not adequately address biases. Even though the Xpert MTB/RIF molecular assay was endorsed a decade ago for simultaneous diagnosis of tuberculosis and RR-TB, the impact of the assay on mortality among people with RR-TB has not yet been assessed. We analysed data of an observational prospective cohort study (EXIT-RIF) performed in South Africa. We applied a causal inference approach using inverse odds of sampling weights to rectify survivor bias and selection bias caused by differing screening guidelines. We also adjusted for confounding using a marginal structural model with inverse probability of treatment weights. We estimated the total effect of an RR-TB diagnosis made by the Xpert assay versus the pre-Xpert diagnostic algorithm (entailing a targeted Line Probe Assay (LPA) among TB-confirmed patients) on two-year mortality and we assessed mediation by RR-treatment initiation. Of the 749 patients diagnosed with RR-TB [247 (33%) by the pre-Xpert diagnostic algorithm and 502 (67%) by the Xpert assay], 42.7% died. Of these, 364 (48.6%) patients died in the pre-Xpert group and 200 (39.8%) in the Xpert group. People diagnosed with RR-TB by the Xpert assay had a higher odds of RR-TB treatment initiation compared to those diagnosed by the targeted LPA-based diagnostic process (OR 2.79; 95%CI 2.19–3.56). Receiving an RR-TB diagnosis by Xpert resulted in a 28% reduction in the odds of mortality within 2 years after presentation to the clinic (OR CI 0.72; 95%CI 0.53–0.99). Causal mediation analysis suggests that the higher rate of RR-TB treatment initiation in people diagnosed by the Xpert assay explains the effect of Xpert on 2-year mortality [natural indirect effect odds ratio 0.90 (95%CI 0.85–0.96). By using causal inference methods in combination with high quality observational data, we could demonstrate that the introduction of the Xpert assay caused a 28% reduction in 2-year odds of mortality of RR-TB. This finding highlights the need for advocacy for a worldwide roll-out of rapid molecular tests. Because the effect is mainly caused by increased RR-TB treatment initiation, health care systems should also ensure timely initiation of effective treatment upon an RR-TB diagnosis.
Autor:innen und Institutionen
- University of Antwerp, Antwerp, Belgium.
- University of North Carolina, Chapel Hill, NC, United States of America.
- University of the Witwatersrand, Johannesburg, South Africa.
- Instituto Nacional de Saúde, Maputo, Mozambique.
- National Health Laboratory Service, Johannesburg, South Africa.
- National Health Laboratory Services, Port Elizabeth, South Africa.
ORCID-Profile: Elise De Vos, Daniel Westreich, Yara Voss de Lima, Pedro da Silva, Annelies Van Rie
Förderung
- Fonds Wetenschappelijk Onderzoek
- Office of AIDS Research
Zitieren
APA
De Vos, E., Westreich, D., Scott, L., Voss de Lima, Y., Stevens, W., Hayes, C., da Silva, P., & Van Rie, A. (2023). Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality. PLOS Global Public Health, 3(9), e0001989. https://doi.org/10.1371/journal.pgph.0001989
Vancouver
De Vos E, Westreich D, Scott L, Voss de Lima Y, Stevens W, Hayes C, et al. Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality. PLOS Global Public Health. 2023;3(9):e0001989. doi:10.1371/journal.pgph.0001989
BibTeX
@article{DeVos2023,
author = {De Vos, Elise and Westreich, Daniel and Scott, Lesley and Voss de Lima, Yara and Stevens, Wendy and Hayes, Cindy and da Silva, Pedro and Van Rie, Annelies},
title = {Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality},
journal = {PLOS Global Public Health},
year = {2023},
volume = {3},
number = {9},
pages = {e0001989},
doi = {10.1371/journal.pgph.0001989}
}
EUVIMED